Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer
NCT01912443 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2014-04-28
Summary
To assess the safety profile of bevacizumab in combination with chemotherapy for the treatment of metastatic colorectal cancer
Conditions
Interventions
- DRUG
-
5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle. Number of Cycles: until progression.
Sponsors & Collaborators
-
Proswell Medical Corporation
collaborator INDUSTRY -
Sun Yat-sen University
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-08-31
- Primary Completion
- 2017-08-31
Countries
- China
Study Locations
More Related Trials
-
Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer
NCT06849362 ·Status: ENROLLING_BY_INVITATION
-
Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients
NCT01554059 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study of Neoadjuvant Chemotherapy Combined With Bevacizumab for Locally Advanced Rectal Cancer
NCT03245203 ·Status: UNKNOWN ·Phase: NA
-
Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
NCT05354674 ·Status: NOT_YET_RECRUITING
-
Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer
NCT05364489 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases
NCT06848842 ·Status: RECRUITING ·Phase: PHASE2
-
The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer
NCT06092242 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer
NCT02487992 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer
NCT01818973 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy
NCT05111860 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
The Effect of ePRO on Quality of Life and Prognosis of Patients With Unresectable Metastatic Colorectal Cancer
NCT04684095 ·Status: UNKNOWN ·Phase: NA
-
Chronic Inflammation, Plasma Proteins Signature, Survival Outcomes and Clinical Response, in Patients Receiving Bevacizumab Combined With Oxaliplatin-based Chemotherapy (Bev/OX) or Bevacizumab Combined With Irinotecan-based Chemotherapy (Bev/IRI)
NCT07241403 ·Status: COMPLETED
-
Study of TCM Syndrome of Hepatocellular Carcinoma and Colorectal Cancer Based on System Science
NCT03189992 ·Status: UNKNOWN ·Phase: PHASE1
-
Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases
NCT05353582 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer
NCT07333053 ·Status: RECRUITING ·Phase: NA
-
Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer
NCT07134218 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
NCT06751914 ·Status: RECRUITING ·Phase: NA
-
Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis
NCT01923987 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer
NCT04466254 ·Status: UNKNOWN ·Phase: PHASE2
-
TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer
NCT06293014 ·Status: RECRUITING ·Phase: PHASE2
-
The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM
NCT03686254 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Exploratory Study of Intermittent Hypoxia Intervention on Colorectal Cancer
NCT06584318 ·Status: RECRUITING ·Phase: NA
-
Mix Vaccine for Metastatic Colorectal Cancer
NCT03357276 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type
NCT02350530 ·Status: COMPLETED ·Phase: PHASE2
-
Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
NCT04835324 ·Status: UNKNOWN